Regeneron’s lung cancer Lag3 lag
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
ASH 2024 – Arcellx is happy to share in Car-T
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
ASH 2024 – AbbVie fights to rise above the BCMA crowd
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
ASH 2024 preview – Arcellx disappoints
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
